PCRX
Pacira Biosciences Inc
NASDAQ · Pharmaceuticals
$21.00
+0.64 (+3.14%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 652.10M | 598.37M | 215.89M | 216.59M | 180.44M |
| Net Income | -92,620,505 | -76,489,681 | 44.13M | 41.33M | 27.91M |
| EPS | — | — | — | — | — |
| Profit Margin | -14.2% | -13.5% | 20.4% | 19.1% | 15.5% |
| Rev Growth | +9.0% | +9.0% | -9.0% | +14.7% | +11.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 193.89M | 193.89M | 335.78M | 314.39M | 342.78M |
| Total Equity | 257.83M | 257.83M | 390.25M | 342.17M | 361.79M |
| D/E Ratio | 0.75 | 0.75 | 0.86 | 0.92 | 0.95 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -8,316,012 | -7,249,230 | 73.70M | 75.27M | 64.71M |
| Free Cash Flow | — | — | 36.97M | 28.35M | 34.26M |